Author: Falzarano, Darryl; de Wit, Emmie; Martellaro, Cynthia; Callison, Julie; Munster, Vincent J.; Feldmann, Heinz
Title: Inhibition of novel ß coronavirus replication by a combination of interferon-a2b and ribavirin Document date: 2013_4_18
ID: tgngoea8_3
Snippet: The rapid identification of therapeutics is a high priority as there is currently no specific therapy or vaccine for nCoV and the resulting disease has been severe with a high case-fatality rate. The clinical experience from SARS suggests that a number of interventions including ribavirin with and without corticosteroids [12] [13] [14] , ribavirin with protease inhibitors 15, 16 and interferon (alfacon-1) with corticosteroids 17 may improve outco.....
Document: The rapid identification of therapeutics is a high priority as there is currently no specific therapy or vaccine for nCoV and the resulting disease has been severe with a high case-fatality rate. The clinical experience from SARS suggests that a number of interventions including ribavirin with and without corticosteroids [12] [13] [14] , ribavirin with protease inhibitors 15, 16 and interferon (alfacon-1) with corticosteroids 17 may improve outcome, but a definitive treatment regimen was not clearly established 18 . Here we address the effectiveness in vitro of two antiviral drugs, interferon-a2b (IFN-a2b) and ribavirin, in an attempt to identify a therapeutic approach that can be immediately utilized in the clinic to benefit future cases.
Search related documents:
Co phrase search for related documents- antiviral drug and case fatality rate: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral drug and clinical experience: 1, 2, 3
- antiviral drug and future case: 1, 2
- antiviral drug and high case fatality rate: 1, 2
- antiviral drug and high priority: 1, 2, 3, 4
- antiviral drug and outcome improve: 1
- antiviral drug and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- antiviral drug and rapid identification: 1, 2, 3, 4, 5, 6, 7
- antiviral drug and result disease: 1, 2, 3, 4
- antiviral drug and specific therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- antiviral drug and therapeutic approach: 1, 2, 3, 4, 5, 6, 7
- antiviral drug and therapeutic rapid identification: 1
- antiviral drug and vaccine specific therapy: 1, 2, 3
- case fatality and clinical experience: 1, 2, 3, 4, 5
- case fatality and future case: 1, 2, 3, 4, 5, 6, 7, 8, 9
- case fatality and high case fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- case fatality and high priority: 1, 2, 3, 4, 5
- case fatality and outcome improve: 1, 2, 3, 4, 5
- case fatality and rapid identification: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date